REGULAR CONTENT
Final ID
405
Type
Original Scientific Research-Oral or Pos
Authors
J Shah1, L Thornton1, J Grajo1, B Toskich1
Institutions
1University of Florida College of Medicine, Gainesville, FL
Purpose
To analyze the safety and efficacy of renal angiomyolipoma (AML) treated with transarterial embolization (TAE).
Materials & Methods
This is a single-center retrospective study of patients with AML treated with TAE from 2007 to 2016. Patients were excluded from the study if a pre-procedure or a post-procedure cross-sectional study was unavailable. Patient demographics, embolic agent, angiographic response, cross-sectional imaging response, length of hospital stay, and complications according to Clavien-Dindo classification were evaluated.
Results
29 patients underwent TAE for AML, but 10 patients were excluded due to insufficient imaging. 19 female patients were included in the study. They underwent 25 successful TAEs, defined as delivery of an embolic agent with >95% flow cessation on post-procedure angiogram. Out of the 19 patients, 17 patients underwent 23 prophylactic TAEs for AML ≥ 4 cm, and two patients underwent TAEs for recent hemorrhage. Out of the 25 TAEs, 19 TAEs were performed with ethanol:ethiodol mixture (50%-70%:50%-30%), two TAEs were performed with embozene particles (100 µm to 400 µm), and four TAEs were performed with a combination of alcohol:ethiodol and bland agent. 52.6% of patients (10/19) demonstrated ≥ 1 cm reduction in longest dimension at first follow-up (median 3 months) while a total of 78.9% of patients (15/19) demonstrated similar reduction by last follow-up (median 25 months). A statistical difference could not be rendered between embolic agents due to small sample size of bland agents. The median hospital stay was 1 day. One patient was admitted for 10 days with respiratory compromise and pneumonia (Clavien-Dindo type II). Two patients had prolonged post-procedure pain requiring oral pain medication for two weeks (Clavien-Dindo type I). One patient requested prophylactic surgical resection one month after TAE. There were no AML hemorrhages after TAE at median follow-up of 12 months (range:1 month to 90 months).
Conclusions
TAE is a safe and effective treatment for AML. 78.9% of patients demonstrated ≥ 1 cm reduction in size by last imaging follow-up (median 25 months). There were no AML hemorrhages after TAE at median follow-up of 12 months.
Final ID
405
Type
Original Scientific Research-Oral or Pos
Authors
J Shah1, L Thornton1, J Grajo1, B Toskich1
Institutions
1University of Florida College of Medicine, Gainesville, FL
Purpose
To analyze the safety and efficacy of renal angiomyolipoma (AML) treated with transarterial embolization (TAE).
Materials & Methods
This is a single-center retrospective study of patients with AML treated with TAE from 2007 to 2016. Patients were excluded from the study if a pre-procedure or a post-procedure cross-sectional study was unavailable. Patient demographics, embolic agent, angiographic response, cross-sectional imaging response, length of hospital stay, and complications according to Clavien-Dindo classification were evaluated.
Results
29 patients underwent TAE for AML, but 10 patients were excluded due to insufficient imaging. 19 female patients were included in the study. They underwent 25 successful TAEs, defined as delivery of an embolic agent with >95% flow cessation on post-procedure angiogram. Out of the 19 patients, 17 patients underwent 23 prophylactic TAEs for AML ≥ 4 cm, and two patients underwent TAEs for recent hemorrhage. Out of the 25 TAEs, 19 TAEs were performed with ethanol:ethiodol mixture (50%-70%:50%-30%), two TAEs were performed with embozene particles (100 µm to 400 µm), and four TAEs were performed with a combination of alcohol:ethiodol and bland agent. 52.6% of patients (10/19) demonstrated ≥ 1 cm reduction in longest dimension at first follow-up (median 3 months) while a total of 78.9% of patients (15/19) demonstrated similar reduction by last follow-up (median 25 months). A statistical difference could not be rendered between embolic agents due to small sample size of bland agents. The median hospital stay was 1 day. One patient was admitted for 10 days with respiratory compromise and pneumonia (Clavien-Dindo type II). Two patients had prolonged post-procedure pain requiring oral pain medication for two weeks (Clavien-Dindo type I). One patient requested prophylactic surgical resection one month after TAE. There were no AML hemorrhages after TAE at median follow-up of 12 months (range:1 month to 90 months).
Conclusions
TAE is a safe and effective treatment for AML. 78.9% of patients demonstrated ≥ 1 cm reduction in size by last imaging follow-up (median 25 months). There were no AML hemorrhages after TAE at median follow-up of 12 months.